Autism Research and Treatment in Proceedings of the 11th Conference on Artiﬁcial Intelligence in Medicine in Europe, R. Bellazzi, A. Abu-Hanna, and J. Hunter, Eds., vol. 4594, pp. 217–226, Amsterdam, The Netherlands, 2007. [12] I. Petricˇ, T. Urbancˇicˇ, B. Cestnik, and M. Macedoni-Luksˇicˇ, “Literature mining method RaJoLink for uncovering relations between biomedical concepts,” Journal of Biomedical Informat- ics, vol. 42, no. 2, pp. 219–227, 2009. [13] B. Fortuna, M. Grobelnik, and D. Mladenic´, “Background knowledge for ontology construction,” in Proceedings of the 3rd European Semantic Web Conference (ESCW ’06), pp. 949–950, Demo, Budva, Montenegro, 2006. [14] K. M. Huber, S. M. Gallagher, S. T. Warren, and M. F. Bear, “Altered synaptic plasticity in a mouse model of fragile X mental retardation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 11, pp. 7746–7750, 2002. [15] R. J. Hagerman, “The physical and behavioural phenotype,” in Fragile X Syndrome, R. J. Hagerman and P. J. Hagerman, Eds., pp. 58–63, The Johns Hopkins University Press, Baltimore, Md, USA, 2002. [16] C. B. Klee, T. H. Crouch, and M. H. Krinks, “Calcineurin: a calcium- and calmodulin-binding protein of the nervous system,” Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 12, pp. 6270–6273, 1979. [17] J. I. Lee and J. Ahnn, “Calcineurin in animal behavior,” Molecules and Cells, vol. 17, no. 3, pp. 390–396, 2004. [18] T. Miyakawa, L. M. Leiter, D. J. Gerber et al., “Conditional cal- cineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 15, pp. 8987–8992, 2003. [19] D. H. Geschwind and P. Levitt, “Autism spectrum disorders: developmental disconnection syndromes,” Current Opinion in Neurobiology, vol. 17, no. 1, pp. 103–111, 2007. [20] P. Jin, R. S. Alisch, and S. T. Warren, “RNA and microRNAs in fragile X mental retardation,” Nature Cell Biology, vol. 6, no. 11, pp. 1048–1053, 2004. [21] C. D’Hulst and R. F. Kooy, “Fragile X syndrome: from molecular genetics to therapy,” Journal of Medical Genetics, vol. 46, no. 9, pp. 577–584, 2009. [22] A. Citri and R. C. Malenka, “Synaptic plasticity: multiple forms, functions, and mechanisms,” Neuropsychopharmacol- ogy, vol. 33, no. 1, pp. 18–41, 2008. [23] S. K. Koekkoek, K. Yamaguchi, B. A. Milojkovic et al., “Dele- tion of FMR1 in purkinje cells enhances parallel ﬁber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome,” Neuron, vol. 4, no. 3, pp. 339–352, 2005. [24] M. F. Bear, K. M. Huber, and S. T. Warren, “The mGluR theory of fragile X mental retardation,” Trends in Neurosciences, vol. 27, no. 7, pp. 370–377, 2004. [25] Y. L. Liu, C. S. Fann, C. M. Liu et al., “More evidence supports the association of PPP3CC with schizophrenia,” Molecular Psychiatry, vol. 12, no. 10, pp. 966–974, 2007. [26] R. Sen and D. Baltimore, “Multiple nuclear factors interact with the immunoglobulin enhancer sequences,” Cell, vol. 46, no. 5, pp. 705–716, 1986. [27] A. Gross, J. M. McDonnell, and S. J. Korsmeyer, “BCL-2 family members and the mitochondria in apoptosis,” Genes and Development, vol. 13, no. 15, pp. 1899–1911, 1999. [28] S. H. Fatemi, J. M. Stary, A. R. Halt, and G. R. Realmuto, “Dys- regulation of reelin and Bcl-2 Proteins in autistic cerebellum,” 7 Journal of Autism and Developmental Disorders, vol. 31, no. 6, pp. 529–535, 2001. [29] M. P. Mattson, “NF-κB in the survival and plasticity of neurons,” Neurochemical Research, vol. 30, no. 6-7, pp. 883– 893, 2005. [30] N. Erin, S. K. Bronson, and M. L. Billingsley, “Calcium- dependent interaction of calcineurin with Bcl-2 in neuronal tissue,” Neuroscience, vol. 117, no. 3, pp. 541–555, 2003. [31] Y. J. Lee, J. C. Chen, A. A. Amoscato et al., “Protective role in Bcl2 in metabolic oxidative stress-induced cell death,” Journal of Cell Science, vol. 114, no. 4, pp. 677–684, 2001. [32] A. Chauhan and V. Chauhan, “Oxidative stress in autism,” Pathophysiology, vol. 13, no. 3, pp. 171–181, 2006. [33] D. A. Rossignol and R. E. Frye, “Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta- analysis,” Molecular Psychiatry, pp. 1–25, 2011. [34] G. Oliveira, L. Diogo, P. Grazina et al., “Mitochondrial dysfunction in autism spectrum disorders: a population-based study,” Developmental Medicine and Child Neurology, vol. 47, no. 3, pp. 185–189, 2005. [35] S. J. Jeon, J. E. Seo, S. Yang et al., “Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades,” Journal of Biomedical Science, vol. 18, no. 1, pp. 17–32, 2011. [36] X. Li, A. Chauhan, A. M. Sheikh et al., “Elevated immune response in the brain of autistic patients,” Journal of Neuroim- munology, vol. 15, no. 1-2, pp. 111–116, 2009. [37] D. L. Vargas, C. Nascimbene, C. Krishnan, A. W. Zimmerman, and C. A. Pardo, “Neuroglial activation and neuroinﬂamma- tion in the brain of patients with autism,” Annals of Neurology, vol. 57, no. 1, pp. 67–81, 2005. [38] A. C. Pardo, “Immunity, neuroglia and neuroinﬂammation in autism,” International Review of Psychiatry, vol. 17, no. 6, pp. 485–495, 2005. [39] P. G. Thomas, M. R. Carter, A. A. Da’dara, T. M. DeSimone, and D. A. Harn, “A helminth glycan induces APC maturation via alternative NF-κ B activation independent of I kappa B alpha degradation,” The Journal of Immunology, vol. 175, no. 4, pp. 2082–2090, 2005. [40] K. S. Ahn and B. B. Aggarwal, “Transcription factor NF-κB: a sensor for smoke and stress signals,” Annals of the New York Academy of Sciences, vol. 1056, pp. 218–233, 2005. [41] I. Thibeault, N. Laﬂamme, and S. Rivest, “Regulation of the gene encoding the monocyte chemoattractant protein 1 (MCP-1) in the mouse and rat brain in response to circulating lps and proinﬂammatory cytokines,” Journal of Comparative Neurology, vol. 434, no. 4, pp. 461–477, 2001. [42] C. Paribello, L. Tao, A. Folino et al., “Open-label add-on treatment trial of minocycline in fragile X syndrome,” BMC Neurology, vol. 10, pp. 91–100, 2010. [43] J. Liu, J. D. Farmer Jr., W. S. Lane, J. Friedman, I. Weissman, and S. L. Schreiber, “Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes,” Cell, vol. 66, no. 4, pp. 807–815, 1991. [44] W. J. Steinbach, J. L. Reedy, R. A. Cramer Jr., J. R. Perfect, and J. Heitman, “Harnessing calcineurin as a novel anti- infective agent against invasive fungal infections,” Nature Reviews Microbiology, vol. 5, no. 6, pp. 418–430, 2007. [45] M. K. Belmonte, G. Allen, A. Beckel-Mitchener, L. M. Boulanger, R. A. Carper, and S. J. Webb, “Autism and abnormal development of brain connectivity,” Journal of Neuroscience, vol. 27, no. 42, pp. 9228–9231, 2004.